Nasal allergen challenge (NAC) is an important tool to diagnose allergic rhinitis. In daily clinical routine, experimentally, or when measuring therapeutic success clinically, nasal allergen challenge is fundamental. It is further one of the key diagnostic tools when initiating specific allergen immunotherapy. So far, national recommendations offered guidance on its execution; however, international divergence left many questions unanswered. These differences in the literature caused EAACI to initiate a task force to answer unmet needs and find a consensus in executing nasal allergen challenge. On the basis of a systematic review containing nasal allergen challenges of the past years, task force members reviewed evidence, discussed open issues, and studied variations of several subjective and objective assessment parameters to propose a standardized way of a nasal allergen challenge procedure in clinical practice. Besides an update on indications, contraindications, and preparations for the test procedure, main recommendations are a bilaterally challenge with standardized allergens, with a spray device offering 0.1 mL per nostril. A systematic catalogue for positivity criteria is given for the variety of established subjective and objective assessment methods as well as a schedule for the challenge procedure. The task force recommends a unified protocol for NAC for daily clinical practice, aiming at eliminating the previous difficulty of comparing NAC results due to unmet needs.

No abstract

Although IC is a resource-intensive methodology, the evaluation of nasal symptoms and signs together with bronchial reactions saves time and expense compared with the organization of multiple individual challenges. We encourage the simultaneous evaluation of both nasal and bronchial reactions in IC tests.

We identified type 1 interferon-regulated proteins as biomarkers in patients with SAR, potentially playing an important role in its pathogenesis. Moreover, when compared with patients with SAR, healthy subjects exhibit an antagonistic proteomic response across seasons, which might prove to be a therapeutic target for disease prevention.

The aim of this pilot research was to investigate acute voice and throat symptoms related to organic dust exposure among nine subjects with suspected occupational rhinitis or asthma. Subjective voice and throat symptoms were recorded before and after an occupational exposure test. In addition, the study included perceptual assessment of subjects' voice samples recorded before and after the exposure tests. The results showed a number of (statistically) significant voice and throat changes in symptoms based on subjects' own assessments. These symptoms included a hoarse, husky, or tense voice, requiring an extra effort when speaking and difficulty in starting phonation (P < 0.05). Other significant symptoms included feeling of shortness of breath or the need to gasp for air and feeling that the voice is weak or that it does not resonate (P < 0.01). Such changes were not, however, detected by voice clinicians in the listening test of subjects' voice samples recorded before and after the exposure. These results suggest that the larynx reacts to organic dust with symptoms that are felt by the patient rather than heard by the voice clinician. The voice disorder in such cases is a diagnosis based on symptoms expressed by subjects.